. Author manuscript; available in PMC: 2019 Dec 17.

Published in final edited form as: Int J Cancer. 2019 Apr 8;146(3):617–626. doi: 10.1002/ijc.32268

Table 4:

3- and 5-year absolute risks of CIN3 and CIN2+, following one positive cotest followed by a negative cotest, adjusted for unresolved positive results^{^}

	N	3-year risk of CIN3		5-year risk of CIN3		3-year risk of CIN2+		5-year risk of CIN2+
	N	Absolute risk	95% CI	Absolute risk	95% CI	Absolute risk	95% CI	Absolute risk	95% CI
1 positive (including HPV-negative ASCUS) followed by 1 negative cotest	6,365	0.019%	(0.000, 0.056)	0.019%	(0.000, 0.056)	0.043%	(0.000, 0.110)	0.176%	(0.000, 0.363)
1 positive (excluding HPV-negative ASCUS) followed by 1 negative cotest	3,456	0.038%	(0.000, 0.108)	0.038%	(0.000, 0.108)	0.067%	(0.000, 0.166)	0.175%	(0.000, 0.392)

Confidence intervals are based on bootstrapping. No women were diagnosed with invasive cervical cancer

^{^}

Assuming women with unresolved positive results are missing at random given their positive result, see Supplementary Materials 2 for details